Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial

Michael O. Harhay, PhD1; Alessandro Gasparini, PhD3; Allan J. Walkey, MD, MS1; Gary E. Weissman, MD, MSHP1,5; Michael J. Crowther, PhD3; Sarah J. Ratcliffe, PhD6; James A. Russell, MD7,8; on behalf of the Vasopressin and Septic Shock Trial (VASST) Investigators

Objectives: Non-mortality septic shock outcomes (e.g., Sequential Organ Failure Assessment score) are important clinical endpoints in pivotal sepsis trials. However, comparisons of observed longitudinal non-mortality outcomes between study groups can be biased if death is unequal between study groups or is associated with an intervention (i.e., informative censoring). We compared the effects of vasopressin versus norepinephrine on the Sequential Organ Failure Assessment score in the Vasopressin and Septic Shock Trial to illustrate the use of joint modeling to help minimize potential bias from informative censoring.

Design: Secondary analysis of the Vasopressin and Septic Shock Trial data.

Setting: Twenty-seven ICUs in Canada, Australia, and United States. Subjects: Seven hundred sixty-three participants with septic shock who received blinded vasopressin (n = 389) or norepinephrine infusions (n = 374).

Measurements and Main Results: Sequential Organ Failure Assessment scores were calculated daily until discharge, death, or day 28 after randomization. Mortality was numerically higher in the norepinephrine arm (28 d mortality of 39% vs 35%; p = 0.25), and there was a positive association between higher Sequential Organ Failure Assessment scores and patient mortality, characteristics that suggest a potential for bias from informative censoring of Sequential Organ Failure Assessment scores by death. The best-fitting joint longitudinal (i.e., linear mixed-effects model) and survival (i.e., Cox proportional hazards model for the time-to-death) model showed that norepinephrine was associated with a more rapid improvement in the total Sequential Organ Failure Assessment score through day 4, and then the daily Sequential Organ Failure Assessment scores converged and overlapped for the remainder of the study period. Conclusions: Short-term reversal of organ dysfunction occurred more rapidly with norepinephrine compared with vasopressin, although differences between study arms did not persist after day 4. Joint models are an accessible methodology that could be used in critical care trials to assess the effects of interventions on the longitudinal progression of key outcomes (e.g., organ dysfunction, biomarkers, or quality of life) that may be informatively truncated by death or other censoring events.

Key Words: joint modeling; organ dysfunction; randomized clinical trial; sepsis; Sequential Organ Failure Assessment
outcome such as the SOFA score presents difficult challenges for trial interpretation. For example, SOFA values may be worse for those who died before death and unmeasured (i.e., missing) after due to the competing risk of death. This type of informative censoring issue creates a missing data problem known as “missing not at random” (MNAR). As a result, comparisons of non-mortality outcomes between study groups can be biased and misleading, particularly if mortality is not equal (i.e., differential) between study groups.

Several approaches can be used to address the problem of informative censoring by competing risks in RCTs (14–16). Investigators can assign fixed values to those that die to create a composite endpoint such as event-free days (17), use an ordinal rank composite outcome such as the Rankin score (18), or a paired outcome ranking system such as the win ratio (19, 20). However, composite outcomes may lose details regarding the component outcomes (21, 22), which complicate their interpretation. So-called “joint models” are an alternative statistical framework that can be used to address the potential problems introduced by informative censoring (23–27), although their use in critical care research has thus far been limited (28–32). The aim of this article is to introduce the use of a joint longitudinal and time-to-event (survival) model approach to analyze critical care trials by evaluating the effects of vasopressin versus norepinephrine on the SOFA score through day 28 in the Vasopressin and Septic Shock Trial (VASST) (33). To support critical care researchers interested in applying this methodology, we have provided statistical code using the open-source R language (34) for statistical computing (Supplementary Digital Content, http://links.lww.com/CCX/A161).

METHODS

Study Design and Participants

This was an unplanned post hoc analysis of VASST (33), a multicenter, double-blind RCT that assigned patients who had septic shock and were receiving a minimum of 5 μg/min of norepinephrine to receive either low-dose vasopressin (0.01–0.03 U/min) or norepinephrine (5–15 μg/min) plus open-label vasopressors. Written informed consent was obtained from all participants. The analysis was approved by the Institutional Review Board at the University of British Columbia.

SOFA Score

The total SOFA score was calculated from the six organ-specific subscores using data recorded in the VASST case report form. Participants with at least one calendar day in which all SOFA subscores were recorded were included in analysis. Intermittent missingness of SOFA subscores before discharge or death was considered to be missing at random (MAR). Missing values after discharge or death were considered MNAR and thus nonignorable.

Rationale for Using a Joint Model

Comparisons of non-mortality longitudinal endpoints (e.g., SOFA) are susceptible to biases from informative censoring or truncation due to death or discharge, or other competing risks that occur during the observation period (14, 35–37). A traditional mixed-effects model is robust to outcomes that are MAR, whereas a joint model can handle data that is MNAR (e.g., from informative censoring) (38, 39). Joint modeling entails the simultaneous estimation of two separate regression models with a shared random effect (see References [23, 24] for a technical tutorial). The most common joint model combination includes a longitudinal (also called “repeated measures” or “mixed-effects models”) and time-to-event (survival) model. The underlying models retain their familiar interpretations. However, the “simultaneous” or “joint” modeling of the longitudinal and survival processes allows each model to inform (i.e., adjust) the other. The sharing of information between the two models can help mitigate potential biases caused by missing outcome data in the longitudinal model (i.e., SOFA score in this study) because the post-randomization event causing missing data is explicitly incorporated in the joint model. This approach to modeling the longitudinal SOFA outcome entails the estimation of an unobserved, or latent, SOFA trajectory that provides an estimate of how the SOFA trajectory may have looked if there was no informative censoring (e.g., death), and all observations were observed.

Statistical Analysis

The focus of our analyses was the comparison of the effects of vasopressin versus norepinephrine on the total SOFA score. To assess the impact of mortality on the treatment effect of vasopressin versus norepinephrine on SOFA score, we fitted a traditional linear mixed-effects model of the SOFA score over time with the same model formulation of the best-fitting joint model for comparison purposes, and several joint longitudinal and survival models using the formulation of Henderson et al (40). SOFA scores for participants were available through their day of hospital discharge, death, or day 28, whichever occurred first. The time-to-event survival data were modeled using a cause-specific Cox proportional hazards model for death. Hence, both discharge and day 28 were considered as censoring events in the death-specific Cox model. Shared random effects were used to capture the association between the longitudinal and time-to-event submodels.

We explored multiple model specifications for the joint model by varying the functional form of time in both the fixed effects in the longitudinal component and the shared random-effects specifications. For instance, we tested linear and quadratic effects, and spline terms with an increasing number of knots (up to 7 and 2 for the fixed effect and random effect of time, respectively). We selected the final model according to the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). ses for the coefficients of the joint model were estimated via 1,000 bootstrap replications with resampling at the participant level. We tested for the modification of treatment by study time by including an interaction term in the longitudinal submodel and by testing its significance using the Wald test. Finally, we performed several sensitivity analyses to assess the robustness of our findings (Supplementary Digital Content, http://links.lww.com/CCX/
Figure 1. Proportion (A) and number (B) of individuals within each Sequential Organ Failure Assessment (SOFA) score subgroup over time in the Vasopressin and Septic Shock Trial. Missing values are included and labeled as not applicable (NA).
A161), including fitting a joint model with a cause-specific model for discharge and a model for either death or discharge.

All models were estimated using the joineRML package (version 0.4.2 [41]) in R (34). Joint models for longitudinal and survival data can also be implemented in other statistical software such as Stata (StataCorp LLC, College Station, TX) (42) and SAS (SAS Institute, Inc., Cary, NC) (43).

RESULTS

In VASST, 779 participants were randomized (397 received vasopressin and 382 norepinephrine). We included 763 participants (97.9%, $n = 389$ vasopressin, $n = 374$ norepinephrine) who had sufficient data to calculate at least one total SOFA score in our analytic sample; eight randomized participants per arm were excluded who did not have a measured SOFA score. Our analytic sample included 6,934 SOFA score measurements ($n = 3,476$ vasopressin, $n = 3,458$ norepinephrine; Fig. 1), with a median of seven SOFA measurements per participant (interquartile interval [IQI], 4–12).

Mean daily SOFA scores throughout the study period are shown in Figure 2 by survival status and in Figure 3 by study arm. As the study period progressed, more SOFA scores were missing or censored, resulting in fewer observations per participant toward the

![Figure 2. Progression of the average total Sequential Organ Failure Assessment (SOFA) score (A) and the SOFA organ subscores (B), overtime among those who survived and died in the Vasopressin and Septic Shock Trial. Survivors are marked by the solid line, and nonsurvivors are marked by the dashed line.](image-url)
end of the study period. Patients who died had higher SOFA scores compared with those who survived (Figs. 2, A and B; median of 13, IQR, 10–15 vs a median of 11, IQR, 8–13; Mann-Whitney U test \( p < 0.01 \)), and patients randomized to receive vasopressin had slower early declines in SOFA than patients receiving norepinephrine alone (Fig. 3A), appearing to be driven by differences in the cardiovascular SOFA subscore (Fig. 3B). In unadjusted analysis, there was a numerically higher 28-day mortality observed in the norepinephrine group (35.0% vs 39.3%; \( \chi^2 \) test \( p = 0.25 \)) (Fig. 4).

**Joint Longitudinal and Survival Analysis**

We examined 36 potential joint model specifications (Supplementary Digital Content, http://links.lww.com/CCX/A161) and selected the best-fitting model using AIC and BIC (Fig. 5). The model with the best fit had the fixed effect of time modeled using a natural spline with 7 degrees of freedom, a random intercept, and a random effect of time modeled using a natural spline with 2 degrees of freedom.

The best-fitting model did not demonstrate an association between vasopressin versus norepinephrine treatment and the survival component of the joint model, consistent with the original findings in the primary trial report that vasopressin did not decrease mortality (hazard ratio of norepinephrine vs vasopressin: 1.15; 95% CI, 0.85–1.46). However, there was a significant association between the longitudinal SOFA score and the risk of death (association parameter = 0.25; \( z \) test \( p < 0.01 \)). This association

![Figure 3](image-url)
indicating that changes in the SOFA score over time were associated with 28-day mortality. The estimated coefficients from the joint model are reported in the Supplementary Digital Content (http://links.lww.com/CCX/A161).

The joint model showed evidence of an interaction between time and treatment, suggesting that the longitudinal evolution of SOFA was different between the vasopressin and norepinephrine groups over time (Fig. 5A) (Wald test \( \chi^2 = 42.0; \ p < 0.01 \)). Specifically, the norepinephrine arm continued to show a larger decrease in the SOFA score than in the vasopressin arm at day 2 (SOFA\text{vasopressin} – SOFA\text{norepinephrine} = 1.17; 95% CI, 0.46–1.87) and day 3 (1.20; 0.42–1.99). However, starting on day 4, the magnitude of the difference in SOFA scores (0.70; –0.03 to 1.42) began to diminish and then overlapped between arms through the end of the follow-up period on day 28 (Fig. 5). Similar results were found using a traditional linear mixed-effects analysis (Fig. 5; e.g., day 2: SOFA\text{vasopressin} – SOFA\text{norepinephrine} = 1.14; 95% CI, 0.70–1.59; and day 3: 1.16; 95% CI, 0.70–1.63.)

Finally, we fit the cause-specific model for the competing risk of discharge using the same formulation for the fixed effects and random effects of the best model selected by the AIC and BIC. The estimated longitudinal SOFA score trajectory was similar to the estimated trajectory from the main analysis model, and the treatment was not associated with the risk of discharge (log hazard ratio, –0.08; 95% CI, –0.40 to 0.24). Our results were also stable when using an any-event (discharge or death) model. A detailed technical summary, including statistical code for replication, additional data summaries, along with a description of joint models in general, and a description specific to our final model, is provided in the Supplementary Digital Content (http://links.lww.com/CCX/A161).

**Figure 4.** Kaplan-Meier survival curves comparing study participants in the vasopressin group and norepinephrine group in the Vasopressin and Septic Shock Trial.

**DISCUSSION**

In this post hoc secondary analysis of the VASST trial, we used joint linear mixed-effects and Cox proportional hazards models to compare the trajectory of SOFA scores over time between the vasopressin and norepinephrine study arms. Despite a small differential occurrence and timing of death between treatment arms (Fig. 4), the findings of joint modeling and conventional modeling with mixed-effects regression were similar (Fig. 5). Both approaches demonstrated that SOFA scores improved more quickly among patients receiving norepinephrine when compared with vasopressin; however, this did not correlate with differences in mortality between arms. Although our use of joint models did not substantively change the interpretation of the VASST trial, we present our findings to demonstrate the potential utility of joint models in future trials in which a larger difference in the competing risk of death (or other censoring events) between trial arms may produce a stronger bias in non-mortality endpoint comparisons.

There is no ideal strategy for dealing with the competing risk of death in critical care trials when a non-mortality outcome is of interest. Unless an intervention truly has no impact on mortality, researchers must consider the potential for bias in non-mortality treatment effect estimates. For example, in a simulation study of methods to compare length of stay, we observed that even small mortality differences (i.e., 2.5% and 5% on the absolute scale) can lead to biased comparisons when using several common statistical models (15). Presently, many trialists deal with the occurrence of death by creating composite endpoints (17, 44). Alternative statistical modeling proposals put forth in the critical care literature include the gamma mixture model (45), the Fine and Gray model (46), principal stratification (47, 48), and the focus of this article, joint longitudinal and time-to-event (or survival) models (28).

We believe that joint models offer several inferential benefits to researchers. Foremost, the underlying longitudinal and survival models retain their well-understood interpretations. Although we used a linear mixed-effects and Cox proportional hazards model in our analysis, the joint modeling framework could be extended to any longitudinal clinical outcome (e.g., blood pressure, fluid balance, urine output, arterial pH, arterial lactate concentration, or daily presence of delirium [28]) and more complex survival models. Different distributions and assumptions would simply use alternate longitudinal (e.g., binary or count data) and/or time-to-event (e.g., competing risks) specifications. Second, adjustment for prognostic variables and center effects can be straightforwardly implemented. Another benefit of the joint model is the adjustment of the mortality analysis to account for the values of the longitudinal outcome (e.g., severity of organ dysfunction) over time (i.e., time-varying covariate adjustment [23, 24]). The use of a joint model may offer particular interpretive benefits over composite endpoints or event-free day measures (e.g., organ failure-free days) (17, 44). For example, although composite endpoints may capture the “net effect” of an intervention, they reduce detailed longitudinal data into a single value, losing benefits that denser and more detailed longitudinal data provide about the trajectory and modification of longitudinal health states due to an intervention (45).
There are limitations and challenges to using the proposed joint modeling approach. First, joint models can be computationally intensive. However, statistical computing in this area is advancing rapidly, making these models increasingly accessible in common software packages. Second, a simple numerical summary of a difference over time may not be straightforward if trajectories are nonlinear, as observed in our study (Fig. 5). Thus, we relied on the assessment of daily differences and visual depictions to summarize our results. Although these strategies can produce clinically informative knowledge, they cannot produce simple summaries that may be desired in some scenarios, such as in a regulatory submission. Third, for illustration, we estimated cause-specific survival models that assumed no competing risks. Thus, survival (or discharge) probabilities estimated from our model would not be informative. Although the use of a cause-specific model does not invalidate our results given the focus on SOFA trajectories overtime, there are several potential questions in critical care where a competing risks specification may be preferable.

Our analysis identified important questions that need to be addressed to support the use of SOFA scores as an outcome. Foremost, there is a need for consensus on a clinically relevant change or difference in SOFA scores between intervention arms. Second, it is unclear how an acute change or difference in SOFA scores between intervention arms translates into long-term non-mortality outcomes (e.g., quality of life). Although we did not observe a short-term mortality benefit associated with SOFA declines in the current study, researchers have shown an association between lower short-term organ dysfunction and improved long-term survival, suggesting that sepsis therapies that reduce short-term organ dysfunction may lead to better long-term outcomes (49, 50). The optimal integration of the SOFA score into critical care trials is an important topic for future research, especially given its use as a primary outcome in recent trials (2, 13).
An additional limitation of our study is that we did not examine the SOFA subscores in the joint model regression framework because the small number of categories (0–4) does not lend itself to straightforward or informative modeling strategies. However, Figure 3B shows that the cardiovascular SOFA score recovery was slower in the vasopressin arm compared with the norepinephrine arm, and this might be what we observed in the overall SOFA score analysis. The calculated vasopressor dose in VASST included both open-label and blinded study drug. Differences in cardiovascular SOFA are not likely due to differences in drug potency because vasopressors were titrated to a mean arterial pressure target in both groups. Differences in early cardiovascular SOFA are also not likely caused by differences in early rates of death (survival curves show overlap of vasopressin and norepinephrine groups until day 10). As such, the explanation for this organ-specific subscore difference is unclear.

To conclude, this reanalysis of the VASST trial provided a case study of how joint longitudinal and survival models could be used to augment assessments of non-mortality outcomes at risk for informative censoring in critical care research. Using the joint modeling framework, we modeled complex, nonlinear relationships of the SOFA score over the course of the VASST trial. Our best-fitting model suggested a slight benefit in improvement of organ dysfunction (as measured by the SOFA score) in the norepinephrine arm compared with vasopressin in the first few days of the study, but this change was not associated with differences in mortality. Although joint modeling did not produce substantially different estimates than traditional modeling methods in this study, we demonstrate the application of joint models in critical care trials. It will be important that researchers who use joint models report their model structure, results, and interpretation clearly and accurately in order to subsequently use the results in future validation studies and evidence synthesis (51).

ACKNOWLEDGMENTS

We thank the patients and families who participated in the Vasopressin and Septic Shock Trial study which has increased our understanding of the treatment of septic shock. We also thank the many dedicated clinicians (doctors, nurses, therapists and others) who cared for these critically ill patients and comforted their families.

Drs. Harhay and Gasparini contributed equally to this work.

All authors helped with conception and design, interpretation of the data, and drafting and revising the article. Dr. Russell helped with acquisition of the data.

Supplemental digital content is available for this article. Direct URL citations appear in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccojournal).

Supported, in part, by grants from U.S. National Institutes of Health (K99 HL141678 and R00 HL141678 [to Dr. Harhay], R01 HL136660 and R01 HL139751 [to Dr. Walkey], K23 HL141639 [Dr. Weisuman], and R01 GM104470 [to Dr. Ratcliffe]). Vasopressin and Septic Shock Trial was funded by Canadian Institutes of Health Research (grant number: MCT 44152; registration number: ISRCTN94856869).

Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of proprotein convertase subtilisin/kexin type 9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. He is an inventor on these patents. He was a founder, Director, and share-holder in Cyon Therapeutics and is a shareholder in Molecular You. He reports receiving consulting fees in the last 3 years from: 1) Asahi Kesai Pharmaceuticals of America (developing recombinant thrombomodulin in sepsis); 2) SIB Therapeutics LLC (developing a sepsis drug); and 3) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). He is no longer actively consulting for the following: 1) La Jolla Pharmaceuticals (developing angiotensin II; he chaired the Data and Safety Monitoring Board of a trial of angiotensin II from 2015 to 2017), no longer actively consulting; 2) Grifols (sells albumin), no longer actively consulting; and 3) PAR Pharma (sells prepared bags of vasopressin), no longer actively consulting. He reports having received an investigator-initiated grant from Grifols (entitled “Is [heparin binding protein] a mechanism of albumin’s efficacy in human septic shock?”) that was provided to and administered by UBC. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: mharhay@penmedicine.upenn.edu

REFERENCES

1. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707–710
2. Fowler AA 3rd, Truwit JD, Hite RD, et al: Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI Randomized Clinical Trial. JAMA 2019; 322:1261–1270
3. Moreno R, Sprung CL, Annane D, et al: Time course of organ failure in patients with septic shock treated with hydrocortisone: Results of the CORTICUS study. Intensive Care Med 2011; 37:1765–1772
4. Annane D, Vignon P, Renault A, et al; CATS Study Group: Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 360:667–684
5. Payen D, Mateo J, Cavaillon JM, et al; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d’Urgence des Hôpitaux extra-Universitaires: Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomised controlled trial. Crit Care Med 2009; 37:803–810
6. Finfer S, McEvoy S, Bellomo R, et al; Safe Study Investigators: Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37:86–96
7. Annane D, Siassi S, Jaber S, et al; CRISTAL Investigators: Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: The CRISTAL randomized trial. JAMA 2013; 310:1809–1817
8. Caironi P, Tognoni G, Masson S, et al; ALBIOS Study Investigators: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370:1412–1421
9. Brunnhorst FM,Engel C, Bloos F, et al; German Competence Network Sepsis (SephNet): Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125–139
10. Myburgh JA, Finfer S, Bellomo R, et al; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group: Hydroxyethyl starch or saline for fluid resuscitation in critically ill patients with hypovolemic shock: The CRISTAL randomized trial. JAMA 2013; 310:1809–1817
11. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055–2064
12. Perner A, Haase N, Guttormsen AB, et al; 6S Trial Group; Scandinavian Critical Care Trials Group: Hydroxethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367:1901–1911
13. ClinicalTrials.gov: ClinicalTrials.gov Identifier: NCT03389555. Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial. Bethesda, MD: National Library of Medicine (US). Available at: https://ClinicalTrials.gov/show/NCT03389555. Accessed November 27, 2019
14. Colantuoni E, Scharfstein DO, Wang C, et al: Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. BMJ 2018; 360:j5748
15. Harhay MO, Ratcliffe SJ, Small DS, et al: Measuring and analyzing length of stay in critical care trials. Med Care 2019; 57:e53–e59
16. Timsit JF, de Kraker MEA, Sommer H, et al; COMBACTE-NET consortium: Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: A perspective from COMBACTE's STAT-Net. Intensive Care Med 2017; 43:1002–1012
17. Schoenfeld DA, Bernard GR; ARDS Network: Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772–1777
18. Broderick JP, Adeeoye O, Elm J: Evolution of the Modified Rankin Scale and its use in future stroke trials. Stroke 2017; 48:2007–2012
19. Novack V, Beiter JR, Yitshak-Sade M, et al: Alive and ventilator free: A hierarchical, composite outcome for clinical trials in the acute respiratory distress syndrome. Crit Care Med 2020; 48:158–166
20. Beiter JR, Sarge T, Banner-Goodspeed VM, et al; EPVent-2 Study Group: Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: A randomized clinical trial. JAMA 2019; 321:846–857
21. Yehya N, Harhay MO, Curley MAQ, et al; COMBACTE-NET consortium: Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: A perspective from COMBACTE's STAT-Net. Intensive Care Med 2017; 43:1002–1012
22. Tomlinson G, Detsky AS: Composite end points in randomized trials: Meaning and time-to-event data: An introductory tutorial. Int J Epidemiol 1994; 50:1003–1014
23. Deslandes E, Chevret S: Joint modeling of multivariate longitudinal data and its relationship to survival time. Stat Sin 2011; 21:557–568
24. Ibrahim JG, Molenberghs G: Missing data methods in longitudinal studies: A review. Test (Madr) 2009; 18:1–43
25. Hernán MA, Robins JM: Causal Inference: What If. Boca Raton, FL, Chapman & Hall/CRC, 2020
26. Tsiatis AA, Davidian M: An overview of joint modeling of longitudinal and survival data. Statistica Neerlandica 2010; 72:34–47
27. Musoro JZ, Zwinderman AH, Abu-Hanna A, et al: Dynamic prediction of mortality among patients in intensive care using the Sequential Organ Failure Assessment (SOFA) score: A joint competing risk survival and longitudinal modeling approach. Statistica Neerlandica 2018; 72:34–47
28. Needham DM, Colantuoni E, Dinglas VD, et al: Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: An ancillary study to a randomised controlled trial. Lancet Respir Med 2016; 4:203–212
29. Russel JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877–887
30. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2020. Available at: http://www.R-project.org/. Accessed November 27, 2019
31. Wang C, Scharfeinstein DO, Colantuoni E, et al: Inference in randomized trials with death and missingness. Biometrics 2017; 73:431–440
32. Little RJ, Rubin DB: Statistical Analysis with Missing Data. Hoboken, NJ, John Wiley & Sons, Inc., 2002
33. Ibrahim JG, Molenberghs G: Missing data methods in longitudinal studies: A review. Test (Madrid) 2009; 18:1–43
34. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2020. Available at: http://www.R-project.org/. Accessed November 27, 2019
35. Angell M, Singer J, Apgar V, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877–887
36. Hernán MA, Robins JM: Causal Inference: What If. Boca Raton, FL, Chapman & Hall/CRC, 2020
37. McConnell S, Stuart EA, Devaney B: The truncation-by-death problem: What to do in an experimental evaluation when the outcome is not always defined. Eval Rev 2008; 32:157–186
38. Little RJ, Rubin DB: Statistical Analysis with Missing Data. Hoboken, NJ, John Wiley & Sons, Inc., 2002
39. Ibrahim JG, Molenberghs G: Missing data methods in longitudinal studies: A review. Test (Madrid) 2009; 18:1–43
40. Bengazzia M, Singer J, Apgar V, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877–887
41. Hickey GL, Philipson P, Jorgensen A, et al; JointRML: A joint model and software package for time-to-event and multivariate longitudinal outcomes. BMC Med Res Methodol 2018; 18:50
42. Crowther MJ, Abrams KR, Lambert PC: Joint modeling of longitudinal and survival data. Stata J 2013; 13:165–184
43. Zhang D, Chen MH, Ibrahim JG, et al; JMate: A SAS macro for joint models of longitudinal and survival data. J Stat Softw 2016; 71:1–24
44. Young B, Hodgson C, Duhlunty J, et al; ANZICS Clinical Trials Groups: End points for phase II trials in intensive care: Recommendations from the Australian and New Zealand Clinical Trials Group consensus panel meeting. Crit Care Resusc 2012; 14:211–215
45. Checkley W, Brower RG, Muñoz A; NIH Acute Respiratory Distress Syndrome Network Investigators: Inference for mutually exclusive competing events through a mixture of generalized gamma distributions. Epidemiology 2010; 21:557–565
46. Bodet-Contentin L, Frasca D, Tavernier E, et al: Ventilator-free day outcomes can be misleading. Crit Care Med 2018; 46:425–429
47. Chiba Y, VanderWeele TJ: A simple method for principal strata effects when the outcome has been truncated due to death. Am J Epidemiol 2011; 173:745–751
48. Hayden D, Pauler DK, Schoenfeld D: An estimator for treatment comparisons among survivors in randomized trials. Biometrics 2005; 61:305–310
49. Linder A, Lee T, Fisher J, et al: Short-term organ dysfunction is associated with long-term (10-Yr) mortality of septic shock. Crit Care Med 2016; 44:e728–e736
50. Schuler A, Wulf DA, Lu Y, et al: The impact of acute organ dysfunction on long-term survival in sepsis. Crit Care Med 2018; 46:843–849
51. Sudell M, Kolamunnage-Donia R, Tudur-Smith C: Joint models for longitudinal and time-to-event data: A review of reporting quality with a view to meta-analysis. BMC Med Res Methodol 2016; 16:168

APPENDIX
In addition to the authors, the following persons and institutions participated in the Vasopressin and Septic Shock Trial (VASST): Executive Committee—J. A. Russell (chair), K. R. Walley, C. L. Holmes Boultin, J. T. Granton, P. C. Hebert, D. J. Cooper, S. Mehta, J. Singer, A. C. Gordon, M. M. Storms (project coordinator), S. Jones (administrative assistant); Management Committee—J. A. Russell (chair), M. M. Storms (project coordinator), K. R. Walley, C. L. Holmes Boultin, J. Singer, A. C. Gordon, S. Jones (administrative assistant); Data and Safety Monitoring Board—G. R. Bernard (chair), A. S. Slutsky, G. A. Wells; Canadian Institutes of Health Research—A. Gasparini; Data Management—J. Singer, B. Savage, D. Ayers, R. Woods, K. Wu, M. Maralit; Monitoring—L. Smith, K. Foley, A. Suri, M. Steinberg, B. Howe, P. Galt, A. Higgins, M. M. Storms; Laboratory—M. E. LeBlanc, A. M. Sutherland, A. Sham, A. McLeod.

Critical Centers and VASST Investigators: Canada: British Columbia: St. Paul’s Hospital—J. A. Russell, K. R. Walley, D. R. Dorschel, M. Hameed, L. Lazosky, S. Helderweirt, K. Foley, C. Honeyman, T. Terins; Vancouver General Hospital—D. Chittock, J. Ronco, L. Smith, S. Logie; Royal Jubilee Hospital—G. Wood F. Auld; Kelowna General Hospital—C. Holmes
Boulton, V. Stedham, M. Mantle, L. Fox, G. D. McCauley, J. D. Rolf, C. Erbacher; Richmond General Hospital—G. Martinka, S. Goulding, S. Silverwood, L. Leung; Royal Columbian Hospital—S. Keenan, J. Murray, M. Van Osch; Manitoba: St. Boniface Hospital—B. Light M. Dominique; Winnipeg Health Science Centre—P. Gray, R. Stimpson, S. Rosser, D. Bell, W. Janz; Ontario: Ottawa Hospital, General Campus—P. C. Hebert, T. McArdle, I. Watpool; University Health Network - Toronto General & Toronto Western Hospitals—J. T. Granton, M. Steinberg, A. Matte-Martyn; St. Joseph’s Hospital—D. J Cook, E. McDonald, F. Clarke, A. Tkaczyk, N. Zytaruk; Mount Sinai Hospital—S. Mehta, T. Stewart, A. Suri, C. Martinez-Motta, R. MacDonald, V. Sivanantham; Ottawa Hospital, Civic Campus—R. Hodder, J. Foxall, M. Lewis; St. Michael’s Hospital—M. Ward, C. Dos Santos, J. Friedrich, D. Scales, O. Smith, I. DeCampos, A. Richards, H. Michalopoulos, U. Bakshi; Sunnybrook and Women’s College Health Science Centre—W. Sibbald (deceased), T. Smith, K. Code, B. Bojilov, C. Dale, M. Keogh; Hamilton Health Sciences Centre—M. Meade, L. Hand; London Health Sciences Centre—C. Martin, J. Kehoe, V. Binns; Sudbury Regional Hospital—M. Mehta, M. McGuire; Charles LeMoyne Hospital—G. Poirier, L. Provost; Windsor - Hotel Dieu Hospital—J. Muscedere, C. Diemer; Australia: Victoria: Alfred Hospital—D. J. Cooper, V. Pellegrino, A. Hilton, S. Morrison, C. Weatherburn, K. Moulden, C. Harry; Royal Melbourne—J. J. Presneill, M. S Robertson, J. F. Cade, B. D. Howe, D. K. Barge, C. A. Boyce, F. Healy; Monash Medical Center—C. Wright, D. Weyandt, J. Barrett, C. Walker, P. Galt, S. Burton; Western Australia: Royal Perth Hospital—G. Dobb, S. Perryman, J. Chamberlain, L. Thomas; South Australia: Flinders Medical Centre: A. Bersten, L. Daly, T. Hunt, D. Wood; United States: Mayo Hospital—B. Patel, J. Larson, M. Rady, G. LeBrun, E. Boyd, R. Rush.